Cases & Deals

Celldex Therapeutics develops worldwide patent portfolios for receptor tyrosine kinase antibody therapeutics

Clients Celldex Therapeutics, Inc.

Jones Day is developing worldwide patent portfolios for Celldex Therapeutics, Inc.'s receptor tyrosine kinase antibody therapeutics, including anti-ErbB3 and anti-KIT antibody clinical candidates.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.